Adeno-associated viruses (AAVs) are the leaders in therapeutic gene delivery, distinguished by their remarkable capacity to efficiently infect a diverse range of cell types. Despite their successes, the industry still grapples with hurdles in producing and characterizing high-quality AAVs at a clinical scale with optimal efficiency. To achieve groundbreaking advancements in therapeutic interventions, advancements in AAV analytical tools are needed. The confluence of PROGEN’s 40-year legacy of reagent expertise with Bio-Techne's automated analytical solutions is a catalyst for redefining the future of gene therapy.
This webinar unveils the transformative power of automation in analytical AAV tools, introducing an era of unparalleled precision, reproducibility, and consistency.